{"id":85255,"date":"2026-06-16T12:15:42","date_gmt":"2026-06-16T12:15:42","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/85255\/"},"modified":"2026-06-16T12:15:42","modified_gmt":"2026-06-16T12:15:42","slug":"novartis-introduces-pluvicto-revolutionary-radioligand-therapy-for-prostate-cancer-in-india-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/85255\/","title":{"rendered":"Novartis Introduces Pluvicto: Revolutionary Radioligand Therapy for Prostate Cancer in India, ETPharma"},"content":{"rendered":"

\"\"\/New Delhi: Swiss pharma major, Novartis<\/a> has announced the commercial launch of its targeted radioligand therapy<\/a>, Pluvicto<\/a> (lutetium Lu 177 vipivotide tetraxetan) for the treatment of prostate cancer in India.<\/p>\n

The novel drug is first to secure approval in India and caters to patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.<\/p>\n

Radioligand therapy (RLT) medicines are a type of precision treatment that pairs a tumor-targeting molecule with a radioactive agent to deliver targeted radiation directly to destroy cancer cells, while sparing healthy tissue.<\/p>\n

The new modality carries a therapeutic radioisotope that helps to damage the cancer cell’s DNA.<\/p>\n

In India the drug will be made available through select hospitals and nuclear medicine centres as part of Novartis\u2019 partnership-led approach. The company is also preparing infrastructure for precision oncology care.<\/p>\n

Notably, RLT medicines are highly time sensitive and proximity to treatment facilities is critical to ensure patients receive their therapy on planned dates.<\/p>\n

Pluvicto is designed to bind the Prostate Specific Membrane Antigen (PSMA)-expressing target cells and the energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and\/or triggering cell death.<\/p>\n

Under its pivotal phase 3 trial (VISION), the drug has demonstrated \u201c38 per cent reduction in the risk of death and a meaningful improvement in progression-free survival compared to standard approaches in eligible patients.” <\/p>\n

Amitabh Dube, Country President and MD Novartis India, said, \u201ca large proportion of prostate cancer patients continue to be diagnosed only after the disease has progressed to a metastatic stage\u2026 With the launch of Pluvicto, we are bringing a globally recognized radioligand therapy platform at a time when the need for precision oncology solutions is increasing rapidly.”<\/p>\n

Novartis onboarded Pluvicto under its $2.1 billion takeover of US-based Endocyte, who had licensed its clinical and commercial rights from Germany\u2019s Advanced Biochemical Compounds (ABX) GmbH for up to $172 million along with the transfer of 2 million shares and additional rights to purchase 4 million shares.<\/p>\n

The drug is manufactured and imported from the comoany’s Spain and Italy-based facilities. In January this year, it announced plans to establish a new plant in Winter Park, Florida, which is expected to become operational by 2029.<\/p>\n

Amid the fading momentum of its heart failure blockbuster, Entresto and unwillingness to join the weight-loss frenzy, the Swiss giant is betting on its radioligand buyouts to power the next leg of growth, led by Pluvicto which racked up $1.9 billion in 2025 and is guided to clock over $5 billion at peak.<\/p>\n

Besides , Pluvicto, Novartis markets another FDA-approved RLT product, Lutathera \u2014lutetium (177Lu) oxodotreotide\u2014 for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET).\n <\/p>\n

Published On Jun 15, 2026 at 01:50 PM IST<\/p>\n

\n Join the community of 2M+ industry professionals.
\n Subscribe to Newsletter to get latest insights & analysis in your inbox.\n <\/p>\n

All about ETPharma industry right on your smartphone! <\/p>\n

\"\"\/ <\/p>\n","protected":false},"excerpt":{"rendered":"New Delhi: Swiss pharma major, Novartis has announced the commercial launch of its targeted radioligand therapy, Pluvicto (lutetium…\n","protected":false},"author":2,"featured_media":85256,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,31818,39442,43415,8514],"class_list":["post-85255","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-pluvicto","tag-prostate-cancer-treatment","tag-psma-positive-prostate-cancer","tag-radioligand-therapy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116759738885383074","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=85255"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85255\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/85256"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=85255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=85255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=85255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}